Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

REFERENCES

• Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, de Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neo-plasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
   Google Scholar
• Shivdasani RA, Hess JL, Skarin AT, Pinkus GS. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol 1993;11:802–811.
   Google Scholar
• Leonard JP, Schattner EJ, Coleman M. Biology and manage-ment of mantle cell lymphoma. Curr Opin Oncol 2001;13:342–347.
   Google Scholar
• Bosch F, Lopez-Guillermo A, Campo E, Ribera JM, Conde E, Ph-is MA, Vallespi T, Woessner S, Montserrat E. Mantle cell lymphoma. Presenting features, response to therapy, and prognostic factors. Cancer 1998;82:567–575.
   Google Scholar
• Pittaluga S, Wlodarska I, Stul MS, Thomas J, Verhoef G, Cassiman jj, van den Berghe H, de Wolf-Peeters C. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopath 1995;26: 17 —24.
   Google Scholar
• Barista I, Romaguera JE, Cabanillas F. Mantle-cell lympho-ma. Lancet Oncol 2001;2:141–148.
   Google Scholar
• Decaudin D, Bosq J, Munck JN, Bayle C, Koscielny S, Boudjmaa S, Bennaceu A, Venuat A-M, Naccache P, Bendalimane B, et al. Mantle-cell lymphomas: character-istics, natural history and prognostic factors of 45 cases. Leuk Lymph 1997;26: 539–550.
   Google Scholar
• Decaudin D. Mantle-cell lymphoma: a biological and therapeutic paradigm. Leuk Lymph 2002;43:773–781.
   Google Scholar
• Khouri IF, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, et al. Hyper-CVAD and high-dose methotrexate/ cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998;16:3803–3809.
   Google Scholar
• Kroger N, Hoffknecht M, Kruger M, Zeller W, Renges H, Shute N, Zschaber R, Zander AR. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000;79:578–580.
   Google Scholar
• Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biological features with three histiologic variants. J Clin Oncol 1997;15:1664— 1671.
   Google Scholar
• Norton AJ, Matthews J, Pappa V, Shamash J, Love S, Rohatiner AZS, Lister TA. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995;6: 249–256.
   Google Scholar
• Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma (including mucosa-associated lymphoid tissue and mono-cytoid B-cell subcategories): A Southwest Oncology Group Study. Blood 1995;85:1075–1082.
   Google Scholar
• Zucca E, Roggero E, Pinotti G, Pedrinis E, Cappella C, Venco A, Cavalli F. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995;6:257–262.
   Google Scholar
• Berger F, Felman P, Sonet A, Sallas G, Bastion Y, Bryon PA, Coiffier B. Non-follicular small B-cell lymphomas: a hetero-geneous group of patients with distinct clinical features and outcome. Blood 1994;83:2829–2835.
   Google Scholar
• Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N, Schlossman R, Kroon M, et al. High dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone mar-row transplantation in mantle-cell lymphoma: no evidence for long term remission. J Clin Oncol 1998;116: 13 — 18.
   Google Scholar
• Argatoff LH, Connors JM, Klasa RJ, Horsman DE, Gascoyne RD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997;89: 2067–2078.
   Google Scholar
• Teodorovic I, Pittaluga S, Kluin-Nelemans JC, Meerwaldt JH, Hagenbeek A, van Glabbehe M, Somers R, Bijnens L, Noordijk EM, de Wolf-Peeters C for the EORTC Lympho-ma Cooperative Group. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic compar-ison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 1995;13: 2819–2826.
   Google Scholar
• Velders GA, Kluin-Nelemans JC, de Boer CJ, Hermans J, Noorkijk EM, Schuuring E, Kramer MHH, van Deijk WA, Kluin PM, van Krieken JHJM. Mantle cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14:1269 — 1274.
   Google Scholar
• Coiffier B. Which treatment for Mantle cell lymphoma patients in 1998? J Clin Oncol 1998;16:3–5.
   Google Scholar
• Densmore jj, Williams ME. Mantle cell lymphoma. Curr Treatment Options Oncol 2000;1:281–287.
   Google Scholar
• Gianni AM, Cortelazzo S, Magni M, Martelli M for the Michelangelo Cooperative. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transp 1 2002;29: S10 — S13.
   Google Scholar
• Vose JM, Bierman PJ, Weisenburger DD, Lynch JC, Bociek G, Armitage JO. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transpl 2000;6:640— 645.
   Google Scholar
• Ratnatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994;84:1050–1055.
   Google Scholar
• Martinez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Perales M, Fernandez F, Montserrat E. Patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation may be rescued by allogeneic transplantation. Bone Marrow Transplant 2000;26:677 —679.
   Google Scholar
• Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non Hodgkin's lymphoma. Bone Marrow Transplant 1997;20:369–374.
   Google Scholar
• Kiss TL, Panzarella T, Messner HA, Meharchand J, Reddy V, Schimmer AD, Lipton JR. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transpl 2002;31:73–78.
   Google Scholar
• Verdonck LF, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-hodgkin's lymphoma. Blood 1997;90:4201 — 4205.
   Google Scholar
• Khouri IF, Lee MS, Romaguera J, Mizra N, Kantarjian H, Korbling M, Albitar M, Giralt S, Samuels B, Anderlini P, et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999;10:1293–1299.
   Google Scholar
• Sohn SK, Baek JH, Kim DH, Jung JT, Kwok DS, Park SH, Suh JS, Lee KB. Successful allogeneic stem-cell transplanta-tion with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. Amer J Hematol 2000; 65:75— 80.
   Google Scholar
• Berdeja JG, Jones RJ, Zahurak ML, Piantadosi S, Abrams RA, Borowitz MJ, Volgesang GB, Noga SJ, Ambinder RF, Flinn IW. Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma. Biol Blood Marrow Transpl 2001;7:561–567.
   Google Scholar
• Jacobsen E, Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem transplantation in mantle cell lymphoma. Curr Opin Oncol 2004;16:106–113.
   Google Scholar
• Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, Pro B, Acholonu A, McLaughlin P, Katz RL,, Champlin RE. Nonablative allogeneic stem-cell transplantation for ad-vanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21:4407–4412.
   Google Scholar